Wellbutrin and Gemtesa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Wellbutrin (bupropion hydrochloride) and Gemtesa (vibegron). Common drug interactions include fatigue among females and fall among males.

The phase IV clinical study analyzes what interactions people have when they take Wellbutrin and Gemtesa. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Wellbutrin?

Wellbutrin has active ingredients of bupropion hydrochloride. It is often used in depression. eHealthMe is studying from 117,115 Wellbutrin users. Check the latest studies of Wellbutrin.

What is Gemtesa?

Gemtesa has active ingredients of vibegron. eHealthMe is studying from 2,648 Gemtesa users. Check the latest studies of Gemtesa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 03, 2026

19 people who take Wellbutrin and Gemtesa together, and have interactions are studied.

Wellbutrin and Gemtesa drug interactions.

What are the common drug interactions of Wellbutrin and Gemtesa, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Headache (pain in head)
  3. Speech disorder
  4. Asthma
  5. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  6. Drug ineffective
  7. Dyspnoea (difficult or laboured respiration)
  8. Fungal infection
  9. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  10. Injection site erythema (redness at injection site)

male:

  1. Fall
  2. Injection site discharge
  3. Injection site pruritus (severe itching at injection site)
  4. Injection site reaction
  5. Injection site swelling
  6. Joint injury
  7. Memory impairment
  8. Peripheral swelling
  9. Rash
  10. Sinusitis (inflammation of sinus)

What are the common drug interactions of Wellbutrin and Gemtesa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Mania (a state of abnormally elevated or irritable mood)

30-39:

n/a

40-49:

  1. Headache (pain in head)
  2. Asthma
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  4. Dyspnoea (difficult or laboured respiration)
  5. Fatigue (feeling of tiredness)
  6. Fungal infection
  7. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  8. Injection site erythema (redness at injection site)
  9. Injection site pruritus (severe itching at injection site)
  10. Injection site rash

50-59:

  1. Clumsiness (a lack of coordination or elegance)
  2. Fall
  3. Injection site discharge
  4. Injection site pain
  5. Pain
  6. Sepsis (a severe blood infection that can lead to organ failure and death)

60+:

  1. Fall
  2. Dizziness
  3. Injection site pruritus (severe itching at injection site)
  4. Injection site reaction
  5. Injection site swelling
  6. Joint injury
  7. Memory impairment
  8. Peripheral swelling
  9. Rash
  10. Sinusitis (inflammation of sinus)

What are the existing conditions these people have? *

  1. Ankylosing Spondylitis (type of arthritis affecting the spine): 4 people, 21.05%
  2. Immunodeficiency Common Variable: 4 people, 21.05%
  3. Incontinence (lack of moderation or self-control): 2 people, 10.53%
  4. Asthma: 2 people, 10.53%
  5. Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 2 people, 10.53%
  6. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 2 people, 10.53%
  7. Urticaria (rash of round, red welts on the skin that itch intensely): 2 people, 10.53%
  8. Idiopathic Urticaria (allergic reactions, presence of hives with unknown cause): 2 people, 10.53%
  9. Spondyloarthropathy (any joint disease of the vertebral column): 2 people, 10.53%
  10. Parkinson's Disease: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Wellbutrin and Gemtesa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Wellbutrin and Gemtesa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Wellbutrin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Gemtesa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Wellbutrin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gemtesa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on bupropion hydrochloride and vibegron (the active ingredients of Wellbutrin and Gemtesa, respectively), and Wellbutrin and Gemtesa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: